BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 25393250)

  • 1. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.
    Liu S; Staats P; Lee M; Alexander HR; Burke AP
    Pathology; 2014 Dec; 46(7):604-9. PubMed ID: 25393250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
    Lee M; Alexander HR; Burke A
    Pathology; 2013 Aug; 45(5):464-73. PubMed ID: 23846294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.
    Krasinskas AM; Borczuk AC; Hartman DJ; Chabot JA; Taub RN; Mogal A; Pingpank J; Bartlett D; Dacic S
    Histopathology; 2016 Apr; 68(5):729-37. PubMed ID: 26272336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.
    Chapel DB; Schulte JJ; Absenger G; Attanoos R; Brcic L; Butnor KJ; Chirieac L; Churg A; Galateau-Sallé F; Hiroshima K; Hung YP; Kindler H; Krausz T; Marchevsky A; Mino-Kenudson M; Mueller J; Nabeshima K; Turaga K; Walts AE; Husain AN
    Mod Pathol; 2021 Feb; 34(2):380-395. PubMed ID: 33060816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
    Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
    Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
    Deraco M; Cabras A; Baratti D; Kusamura S
    Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study.
    Xing D; Banet N; Sharma R; Vang R; Ronnett BM; Illei PB
    Hum Pathol; 2018 Feb; 72():160-166. PubMed ID: 29241740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women. A clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors.
    Goldblum J; Hart WR
    Am J Surg Pathol; 1995 Oct; 19(10):1124-37. PubMed ID: 7573671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact on survival of nuclear atypia in epithelioid malignant mesothelioma.
    Mlika M; Limam M; Benzarti A; Mezni F
    Adv Respir Med; 2019; 87(2):90-95. PubMed ID: 31038719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility for histologic parameters in peritoneal mesothelioma.
    Hartman DJ; Borczuk A; Dacic S; Krasinskas A
    Hum Pathol; 2017 Sep; 67():54-59. PubMed ID: 28712777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
    Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
    Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Malignant Deciduoid Mesothelioma: A Challenging Diagnosis.
    Regragui M; Guebessi NB
    Arch Pathol Lab Med; 2019 Apr; 143(4):531-533. PubMed ID: 30500290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Well-differentiated papillary mesothelioma with invasive foci.
    Churg A; Allen T; Borczuk AC; Cagle PT; Galateau-Sallé F; Hwang H; Murer B; Murty VV; Ordonez N; Tazelaar HD; Wick M
    Am J Surg Pathol; 2014 Jul; 38(7):990-8. PubMed ID: 24618613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal Deciduoid Malignant Mesothelioma on 67Ga SPECT/CT.
    Lai YC; Wu YC; Kao CH; Hsieh TC; Sun SS
    Clin Nucl Med; 2019 Feb; 44(2):161-163. PubMed ID: 30394926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcomatoid Peritoneal Mesothelioma: Clinicopathologic Correlation of 13 Cases.
    Pavlisko EN; Roggli VL
    Am J Surg Pathol; 2015 Nov; 39(11):1568-75. PubMed ID: 26371785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
    Singhi AD; Krasinskas AM; Choudry HA; Bartlett DL; Pingpank JF; Zeh HJ; Luvison A; Fuhrer K; Bahary N; Seethala RR; Dacic S
    Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.